Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 251

1.

Point-Counterpoint: Should serum β-D- glucan testing be used for the diagnosis of Pneumocystis jiroveci pneumonia?

Corsi-Vasquez G, Ostrosky-Zeichner L, Pilkington EF 3rd, Sax PE.

J Clin Microbiol. 2019 Aug 21. pii: JCM.01340-19. doi: 10.1128/JCM.01340-19. [Epub ahead of print]

PMID:
31434728
2.

Nearly Two Decades Later, Exciting Progress in HIV, But Challenges Remain.

Sax PE.

Infect Dis Clin North Am. 2019 Sep;33(3):xiii-xiv. doi: 10.1016/j.idc.2019.05.010. No abstract available.

PMID:
31395148
3.

A Disturbing Decline.

Braun DA, Henderson GV, Sax PE, Miller AL, Loscalzo J.

N Engl J Med. 2019 Jun 6;380(23):2257-2262. doi: 10.1056/NEJMcps1807619. No abstract available.

PMID:
31167056
4.

A Disturbing Decline.

Braun DA, Simchowitz B, Henderson GV, Sax PE, Vaidya A.

N Engl J Med. 2019 May 30;380(22):e42. doi: 10.1056/NEJMimc1807627. No abstract available.

PMID:
31141638
5.

ART reduces T cell activation and immune exhaustion markers in HIV controllers.

Li JZ, Segal FP, Bosch RJ, Lalama CM, Roberts-Toler C, Delagreverie H, Getz R, Garcia-Broncano P, Kinslow J, Tressler R, Van Dam CN, Keefer M, Carrington M, Lichterfeld M, Kuritzkes D, Yu XG, Landay A, Sax PE; AIDS Clinical Trials Group Study A5308 Team.

Clin Infect Dis. 2019 May 25. pii: ciz442. doi: 10.1093/cid/ciz442. [Epub ahead of print]

PMID:
31131858
6.

Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial.

Stellbrink HJ, Arribas JR, Stephens JL, Albrecht H, Sax PE, Maggiolo F, Creticos C, Martorell CT, Wei X, Acosta R, Collins SE, Brainard D, Martin H.

Lancet HIV. 2019 Jun;6(6):e364-e372. doi: 10.1016/S2352-3018(19)30080-3. Epub 2019 May 5.

PMID:
31068272
7.

Clinical impact and cost-effectiveness of genotype testing at HIV diagnosis in the United States.

Hyle EP, Scott JA, Sax PE, Millham LRI, Dugdale CM, Weinstein MC, Freedberg KA, Walensky RP.

Clin Infect Dis. 2019 May 4. pii: ciz372. doi: 10.1093/cid/ciz372. [Epub ahead of print]

PMID:
31055599
8.

Health Considerations for HIV-Infected International Travelers.

Bourque DL, Solomon DA, Sax PE.

Curr Infect Dis Rep. 2019 Apr 12;21(5):16. doi: 10.1007/s11908-019-0672-y. Review.

PMID:
30980287
9.

Risks and Benefits of Dolutegravir- and Efavirenz-Based Strategies for South African Women With HIV of Child-Bearing Potential: A Modeling Study.

Dugdale CM, Ciaranello AL, Bekker LG, Stern ME, Myer L, Wood R, Sax PE, Abrams EJ, Freedberg KA, Walensky RP.

Ann Intern Med. 2019 May 7;170(9):614-625. doi: 10.7326/M18-3358. Epub 2019 Apr 2.

PMID:
30934067
10.

Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials.

Gupta SK, Post FA, Arribas JR, Eron JJ Jr, Wohl DA, Clarke AE, Sax PE, Stellbrink HJ, Esser S, Pozniak AL, Podzamczer D, Waters L, Orkin C, Rockstroh JK, Mudrikova T, Negredo E, Elion RA, Guo S, Zhong L, Carter C, Martin H, Brainard D, SenGupta D, Das M.

AIDS. 2019 Jul 15;33(9):1455-1465. doi: 10.1097/QAD.0000000000002223.

11.

No Significant Changes to Residual Viremia After Switch to Dolutegravir and Lamivudine in a Randomized Trial.

Li JZ, Sax PE, Marconi VC, Fajnzylber J, Berzins B, Nyaku AN, Fichtenbaum CJ, Wilkin T, Benson CA, Koletar SL, Lorenzo-Redondo R, Taiwo BO.

Open Forum Infect Dis. 2019 Feb 11;6(3):ofz056. doi: 10.1093/ofid/ofz056. eCollection 2019 Mar.

12.

Middle-Aged Men With HIV Have Diminished Accelerometry-Based Activity Profiles Despite Similar Lab-Measured Gait Speed: Pilot Study.

Hale TM, Guardigni V, Roitmann E, Vegreville M, Brawley B, Woodbury E, Storer TW, Sax PE, Montano M.

JMIR Mhealth Uhealth. 2019 Feb 1;7(2):e11190. doi: 10.2196/11190.

13.

Dolutegravir plus lamivudine for initial treatment of HIV-1-infected participants with HIV-1 RNA <500 000 copies/mL: week 48 outcomes from ACTG 5353.

Nyaku AN, Zheng L, Gulick RM, Olefsky M, Berzins B, Wallis CL, Godfrey C, Sax PE, Acosta EP, Haas DW, Smith KY, Sha BE, Van Dam CN, Taiwo BO; ACTG A5353 Study Team .

J Antimicrob Chemother. 2019 May 1;74(5):1376-1380. doi: 10.1093/jac/dky564.

PMID:
30668695
14.

Race/Ethnicity and Protease Inhibitor Use Influence Plasma Tenofovir Exposure in Adults Living with HIV-1 in AIDS Clinical Trials Group Study A5202.

Bednasz CJ, Venuto CS, Ma Q, Daar ES, Sax PE, Fischl MA, Collier AC, Smith KY, Tierney C, Acosta EP, Mager DE, Morse GD; AIDS Clinical Trials Group Study A5202 Team.

Antimicrob Agents Chemother. 2019 Mar 27;63(4). pii: e01638-18. doi: 10.1128/AAC.01638-18. Print 2019 Apr.

PMID:
30642925
15.

Generalizing Evidence from Randomized Trials using Inverse Probability of Sampling Weights.

Buchanan AL, Hudgens MG, Cole SR, Mollan KR, Sax PE, Daar ES, Adimora AA, Eron JJ, Mugavero MJ.

J R Stat Soc Ser A Stat Soc. 2018 Oct;181(4):1193-1209. doi: 10.1111/rssa.12357. Epub 2018 Feb 26.

PMID:
30555215
16.

Relationships Between Adipose Mitochondrial Function, Serum Adiponectin, and Insulin Resistance in Persons With HIV After 96 Weeks of Antiretroviral Therapy.

Hulgan T, Ramsey BS, Koethe JR, Samuels DC, Gerschenson M, Libutti DE, Sax PE, Daar ES, McComsey GA, Brown TT.

J Acquir Immune Defic Syndr. 2019 Mar 1;80(3):358-366. doi: 10.1097/QAI.0000000000001926.

PMID:
30531304
17.

Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate is Non-inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-naive Adults With Human Immunodeficiency Virus-1 Infection: Week 48 Results of the DRIVE-AHEAD Trial.

Orkin C, Squires KE, Molina JM, Sax PE, Wong WW, Sussmann O, Kaplan R, Lupinacci L, Rodgers A, Xu X, Lin G, Kumar S, Sklar P, Nguyen BY, Hanna GJ, Hwang C, Martin EA; DRIVE-AHEAD Study Group.

Clin Infect Dis. 2019 Feb 1;68(4):535-544. doi: 10.1093/cid/ciy540.

18.

Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2018 Recommendations of the International Antiviral Society-USA Panel.

Saag MS, Benson CA, Gandhi RT, Hoy JF, Landovitz RJ, Mugavero MJ, Sax PE, Smith DM, Thompson MA, Buchbinder SP, Del Rio C, Eron JJ Jr, Fätkenheuer G, Günthard HF, Molina JM, Jacobsen DM, Volberding PA.

JAMA. 2018 Jul 24;320(4):379-396. doi: 10.1001/jama.2018.8431.

19.

Brain neurotransmitter transporter/receptor genomics and efavirenz central nervous system adverse events.

Haas DW, Bradford Y, Verma A, Verma SS, Eron JJ, Gulick RM, Riddler SA, Sax PE, Daar ES, Morse GD, Acosta EP, Ritchie MD.

Pharmacogenet Genomics. 2018 Jul;28(7):179-187. doi: 10.1097/FPC.0000000000000341.

20.

Coformulated bictegravir, emtricitabine, tenofovir alafenamide after initial treatment with bictegravir or dolutegravir and emtricitabine/tenofovir alafenamide.

Sax PE, DeJesus E, Crofoot G, Ward D, Benson P, Dretler R, Mills A, Brinson C, Wei X, Collins SE, Cheng A.

AIDS. 2018 Jul 31;32(12):1723-1725. doi: 10.1097/QAD.0000000000001894.

21.

Raltegravir 1200 mg Once Daily vs 400 mg Twice Daily, With Emtricitabine and Tenofovir Disoproxil Fumarate, for Previously Untreated HIV-1 Infection: Week 96 Results From ONCEMRK, a Randomized, Double-Blind, Noninferiority Trial.

Cahn P, Sax PE, Squires K, Molina JM, Ratanasuwan W, Rassool M, Bloch M, Xu X, Zhou Y, Homony B, Hepler D, Teppler H, Hanna GJ, Nguyen BY, Greaves W; ONCEMRK Study Group.

J Acquir Immune Defic Syndr. 2018 Aug 15;78(5):589-598. doi: 10.1097/QAI.0000000000001723.

22.

Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial.

Molina JM, Squires K, Sax PE, Cahn P, Lombaard J, DeJesus E, Lai MT, Xu X, Rodgers A, Lupinacci L, Kumar S, Sklar P, Nguyen BY, Hanna GJ, Hwang C; DRIVE-FORWARD Study Group.

Lancet HIV. 2018 May;5(5):e211-e220. doi: 10.1016/S2352-3018(18)30021-3. Epub 2018 Mar 25.

PMID:
29592840
23.

Atypical Skeletal Muscle Profiles in Human Immunodeficiency Virus-Infected Asymptomatic Middle-Aged Adults.

Tran T, Guardigni V, Pencina KM, Amato AA, Floyd M, Brawley B, Mozeleski B, McKinnon J, Woodbury E, Heckel E, Li Z, Storer T, Sax PE, Montano M.

Clin Infect Dis. 2018 Jun 1;66(12):1918-1927. doi: 10.1093/cid/cix1121.

24.

Dolutegravir Plus Lamivudine Maintains Human Immunodeficiency Virus-1 Suppression Through Week 48 in a Pilot Randomized Trial.

Taiwo BO, Marconi VC, Berzins B, Moser CB, Nyaku AN, Fichtenbaum CJ, Benson CA, Wilkin T, Koletar SL, Colasanti J, Acosta EP, Li JZ, Sax PE.

Clin Infect Dis. 2018 May 17;66(11):1794-1797. doi: 10.1093/cid/cix1131.

25.

ACTG A5353: A Pilot Study of Dolutegravir Plus Lamivudine for Initial Treatment of Human Immunodeficiency Virus-1 (HIV-1)-infected Participants With HIV-1 RNA <500000 Copies/mL.

Taiwo BO, Zheng L, Stefanescu A, Nyaku A, Bezins B, Wallis CL, Godfrey C, Sax PE, Acosta E, Haas D, Smith KY, Sha B, Van Dam C, Gulick RM.

Clin Infect Dis. 2018 May 17;66(11):1689-1697. doi: 10.1093/cid/cix1083.

26.

Efavirenz Therapeutic Range in HIV-1 Treatment-Naive Participants.

Bednasz CJ, Venuto CS, Ma Q, Daar ES, Sax PE, Fischl MA, Collier AC, Smith KY, Tierney C, Yang Y, Wilding GE, Morse GD.

Ther Drug Monit. 2017 Dec;39(6):596-603. doi: 10.1097/FTD.0000000000000443.

27.

The Clinical and Economic Impact of Attaining National HIV/AIDS Strategy Treatment Targets in the United States.

Borre ED, Hyle EP, Paltiel AD, Neilan AM, Sax PE, Freedberg KA, Weinstein MC, Walensky RP.

J Infect Dis. 2017 Oct 17;216(7):798-807. doi: 10.1093/infdis/jix349.

28.

Conflicting effects of atazanavir therapy on atherosclerotic risk factors in stable HIV patients: A randomized trial of regimen switch to atazanavir.

Beckman JA, Wood BR, Ard KL, Price CN, Solomon DA, Zuflacht JP, Milian J, Prenner JC, Sax PE.

PLoS One. 2017 Oct 12;12(10):e0181993. doi: 10.1371/journal.pone.0181993. eCollection 2017.

29.

Race/Ethnicity and the Pharmacogenetics of Reported Suicidality With Efavirenz Among Clinical Trials Participants.

Mollan KR, Tierney C, Hellwege JN, Eron JJ, Hudgens MG, Gulick RM, Haubrich R, Sax PE, Campbell TB, Daar ES, Robertson KR, Ventura D, Ma Q, Edwards DRV, Haas DW; AIDS Clinical Trials Group.

J Infect Dis. 2017 Sep 1;216(5):554-564. doi: 10.1093/infdis/jix248.

30.

Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial.

Cahn P, Kaplan R, Sax PE, Squires K, Molina JM, Avihingsanon A, Ratanasuwan W, Rojas E, Rassool M, Bloch M, Vandekerckhove L, Ruane P, Yazdanpanah Y, Katlama C, Xu X, Rodgers A, East L, Wenning L, Rawlins S, Homony B, Sklar P, Nguyen BY, Leavitt R, Teppler H; ONCEMRK Study Group.

Lancet HIV. 2017 Nov;4(11):e486-e494. doi: 10.1016/S2352-3018(17)30128-5. Epub 2017 Sep 11.

PMID:
28918877
31.

Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial.

Sax PE, Pozniak A, Montes ML, Koenig E, DeJesus E, Stellbrink HJ, Antinori A, Workowski K, Slim J, Reynes J, Garner W, Custodio J, White K, SenGupta D, Cheng A, Quirk E.

Lancet. 2017 Nov 4;390(10107):2073-2082. doi: 10.1016/S0140-6736(17)32340-1. Epub 2017 Aug 31.

PMID:
28867499
32.

Cardiovascular outcomes among HIV-infected veterans receiving atazanavir.

LaFleur J, Bress AP, Rosenblatt L, Crook J, Sax PE, Myers J, Ritchings C.

AIDS. 2017 Sep 24;31(15):2095-2106. doi: 10.1097/QAD.0000000000001594.

33.

Setting Performance Standards for a Cost-Effective Human Immunodeficiency Virus Cure Strategy in South Africa.

Paltiel AD, Zheng A, Weinstein MC, Gaynes MR, Wood R, Freedberg KA, Sax PE, Walensky RP.

Open Forum Infect Dis. 2017 Apr 22;4(2):ofx081. doi: 10.1093/ofid/ofx081. eCollection 2017 Spring.

34.

Projecting 10-year, 20-year, and Lifetime Risks of Cardiovascular Disease in Persons Living With Human Immunodeficiency Virus in the United States.

Losina E, Hyle EP, Borre ED, Linas BP, Sax PE, Weinstein MC, Rusu C, Ciaranello AL, Walensky RP, Freedberg KA.

Clin Infect Dis. 2017 Oct 15;65(8):1266-1271. doi: 10.1093/cid/cix547.

35.

Should We Be Testing for Baseline Integrase Resistance in Patients Newly Diagnosed With Human Immunodeficiency Virus?

Koullias Y, Sax PE, Fields NF, Walensky RP, Hyle EP.

Clin Infect Dis. 2017 Oct 15;65(8):1274-1281. doi: 10.1093/cid/cix542.

36.

Impact of Medication Adherence on Virologic Failure in A5202: A Randomized, Partially Blinded, Phase 3B Study.

Parker RA, Rabideau DJ, Sax PE, Tierney C, Daar ES, Collier AC, Losina E, Freedberg KA.

Clin Infect Dis. 2017 Jun 1;64(11):1612-1614. doi: 10.1093/cid/cix176.

37.

Brief Report: Randomized, Double-Blind Comparison of Tenofovir Alafenamide (TAF) vs Tenofovir Disoproxil Fumarate (TDF), Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine (E/C/F) for Initial HIV-1 Treatment: Week 144 Results.

Arribas JR, Thompson M, Sax PE, Haas B, McDonald C, Wohl DA, DeJesus E, Clarke AE, Guo S, Wang H, Callebaut C, Plummer A, Cheng A, Das M, McCallister S.

J Acquir Immune Defic Syndr. 2017 Jun 1;75(2):211-218. doi: 10.1097/QAI.0000000000001350.

PMID:
28282300
38.

Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial.

Sax PE, DeJesus E, Crofoot G, Ward D, Benson P, Dretler R, Mills A, Brinson C, Peloquin J, Wei X, White K, Cheng A, Martin H, Quirk E.

Lancet HIV. 2017 Apr;4(4):e154-e160. doi: 10.1016/S2352-3018(17)30016-4. Epub 2017 Feb 15.

PMID:
28219610
39.

Ledipasvir-sofosbuvir and sofosbuvir plus ribavirin in patients with chronic hepatitis C and bleeding disorders.

Walsh CE, Workowski K, Terrault NA, Sax PE, Cohen A, Bowlus CL, Kim AY, Hyland RH, Han B, Wang J, Stamm LM, Brainard DM, McHutchison JG, von Drygalski A, Rhame F, Fried MW, Kouides P, Balba G, Reddy KR.

Haemophilia. 2017 Mar;23(2):198-206. doi: 10.1111/hae.13178. Epub 2017 Jan 25.

PMID:
28124511
40.

Improving on effective antiretroviral therapy: how good will a cure have to be?

Freedberg KA, Sax PE.

J Med Ethics. 2017 Feb;43(2):71-73. doi: 10.1136/medethics-2016-103907. Epub 2016 Dec 5. No abstract available.

41.

Testing Limits.

Massarotti EM, Sax PE, Compton L, Levy BD, Loscalzo J.

N Engl J Med. 2016 Oct 6;375(14):1383-1388. No abstract available.

PMID:
27705260
42.

Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2016 Recommendations of the International Antiviral Society-USA Panel.

Günthard HF, Saag MS, Benson CA, del Rio C, Eron JJ, Gallant JE, Hoy JF, Mugavero MJ, Sax PE, Thompson MA, Gandhi RT, Landovitz RJ, Smith DM, Jacobsen DM, Volberding PA.

JAMA. 2016 Jul 12;316(2):191-210. doi: 10.1001/jama.2016.8900.

43.

Nonnucleoside Reverse-transcriptase Inhibitor- vs Ritonavir-boosted Protease Inhibitor-based Regimens for Initial Treatment of HIV Infection: A Systematic Review and Metaanalysis of Randomized Trials.

Borges ÁH, Lundh A, Tendal B, Bartlett JA, Clumeck N, Costagliola D, Daar ES, Echeverría P, Gisslén M, Huedo-Medina TB, Hughes MD, Huppler Hullsiek K, Khabo P, Komati S, Kumar P, Lockman S, MacArthur RD, Maggiolo F, Matteelli A, Miro JM, Oka S, Petoumenos K, Puls RL, Riddler SA, Sax PE, Sierra-Madero J, Torti C, Lundgren JD.

Clin Infect Dis. 2016 Jul 15;63(2):268-80. doi: 10.1093/cid/ciw236. Epub 2016 Apr 18. Review.

44.

Brief Report: A Randomized, Double-Blind Comparison of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate, Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine for Initial HIV-1 Treatment: Week 96 Results.

Wohl D, Oka S, Clumeck N, Clarke A, Brinson C, Stephens J, Tashima K, Arribas JR, Rashbaum B, Cheret A, Brunetta J, Mussini C, Tebas P, Sax PE, Cheng A, Zhong L, Callebaut C, Das M, Fordyce M; GS-US-2,92-01040111 and Study Team.

J Acquir Immune Defic Syndr. 2016 May 1;72(1):58-64. doi: 10.1097/QAI.0000000000000940.

PMID:
26829661
45.

The Cost-effectiveness and Budget Impact of 2-Drug Dolutegravir-Lamivudine Regimens for the Treatment of HIV Infection in the United States.

Girouard MP, Sax PE, Parker RA, Taiwo B, Freedberg KA, Gulick RM, Weinstein MC, Paltiel AD, Walensky RP.

Clin Infect Dis. 2016 Mar 15;62(6):784-91. doi: 10.1093/cid/civ981. Epub 2015 Dec 9.

46.

Prioritizing HIV comparative effectiveness trials based on value of information: generic versus brand-name ART in the US.

Pei PP, Weinstein MC, Li XC, Hughes MD, Paltiel AD, Hou T, Parker RA, Gaynes MR, Sax PE, Freedberg KA, Schackman BR, Walensky RP.

HIV Clin Trials. 2015 Nov;16(6):207-18. doi: 10.1080/15284336.2015.1123942. Epub 2015 Dec 11.

47.

Improving Influenza and Pneumococcal Vaccination Rates in Ambulatory Specialty Practices.

Pennant KN, Costa JJ, Fuhlbrigge AL, Sax PE, Szent-Gyorgyi LE, Coblyn J, Desai SP.

Open Forum Infect Dis. 2015 Oct 1;2(4):ofv119. doi: 10.1093/ofid/ofv119. eCollection 2015 Dec.

48.

CLINICAL PROBLEM-SOLVING. On the Nose.

Abdalla M, Sax PE, Mostaghimi A, Miller AL, Loscalzo J.

N Engl J Med. 2015 Sep 3;373(10):955-61. doi: 10.1056/NEJMcps1315433. No abstract available.

PMID:
26332551
49.

Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1.

Naggie S, Cooper C, Saag M, Workowski K, Ruane P, Towner WJ, Marks K, Luetkemeyer A, Baden RP, Sax PE, Gane E, Santana-Bagur J, Stamm LM, Yang JC, German P, Dvory-Sobol H, Ni L, Pang PS, McHutchison JG, Stedman CA, Morales-Ramirez JO, Bräu N, Jayaweera D, Colson AE, Tebas P, Wong DK, Dieterich D, Sulkowski M; ION-4 Investigators.

N Engl J Med. 2015 Aug 20;373(8):705-13. doi: 10.1056/NEJMoa1501315. Epub 2015 Jul 21.

50.

Pink plaque on the arm of a man after a trip to Mexico: cutaneous leishmaniasis.

Cohen JM, Saavedra AP, Sax PE, Lipworth AD.

Dermatol Online J. 2015 Jun 16;21(6). pii: 13030/qt5jn0w4pd.

PMID:
26158361

Supplemental Content

Support Center